PD-1/PD-L1 Blockade Therapy for Tumors with Downregulated MHC Class I Expression
Department of Genetics and Microbiology, Faculty of Science, Charles University, BIOCEV, Průmyslová 595, 25250 Vestec, Czech Republic
Int. J. Mol. Sci. 2017, 18(6), 1331; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms18061331
Received: 26 May 2017 / Revised: 12 June 2017 / Accepted: 17 June 2017 / Published: 21 June 2017
(This article belongs to the Special Issue Targeting Immune Checkpoints and Immunotherapy)
The therapy of different advanced-stage malignancies with monoclonal antibodies blocking programmed cell death protein 1 (PD-1)/PD-1 ligand 1 (PD-L1) signaling has had an impressive long-lasting effect in a portion of patients, but in most cases, this therapy was not successful, or a secondary resistance developed. To enhance its efficacy in treated patients, predictive biomarkers are searched for and various combination treatments are intensively investigated. As the downregulation of major histocompatibility complex (MHC) class I molecules is one of the most frequent mechanisms of tumor escape from the host’s immunity, it should be considered in PD-1/PD-L1 checkpoint inhibition. The potential for the use of a PD-1/PD-L1 blockade in the treatment of tumors with aberrant MHC class I expression is discussed, and some strategies of combination therapy are suggested.
View Full-Text
Keywords:
PD-1; PD-L1; checkpoint blockade; MHC class I; tumor escape; cancer immunotherapy; biomarker; interferon gamma
▼
Show Figures
Graphical abstract
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited
MDPI and ACS Style
Šmahel, M. PD-1/PD-L1 Blockade Therapy for Tumors with Downregulated MHC Class I Expression. Int. J. Mol. Sci. 2017, 18, 1331. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms18061331
AMA Style
Šmahel M. PD-1/PD-L1 Blockade Therapy for Tumors with Downregulated MHC Class I Expression. International Journal of Molecular Sciences. 2017; 18(6):1331. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms18061331
Chicago/Turabian StyleŠmahel, Michal. 2017. "PD-1/PD-L1 Blockade Therapy for Tumors with Downregulated MHC Class I Expression" Int. J. Mol. Sci. 18, no. 6: 1331. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms18061331
Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.
Search more from Scilit
